RecruitingRecruiting
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
NCT07616206 · vTv Therapeutics
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study
About this study
TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.
Eligibility criteria
Key Inclusion Criteria:
* Participants \>= 18 years of age
* Fasting C-peptide levels \<0.6 ng/ml
* Average TIR \< 70% recorded on their personal CGM data collected over the past 7 days prior to Visit 1
* Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
* Willing to wear a study provided CGM for study duration
* Total bilirubin ≤2×ULN, ALT and AST ≤3×ULN
Key Exclusion Criteria:
* Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
* Have been hospitalized for DKA within 3 months
* Have uncontrolled hypothyroidism or hyperthyroidism
* Have QTcF interval \> 450 msec for males or \> 470 msec for females
* Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
* Have persistent, uncontrolled hypertension
* Have clinically significant cardiovascular or cerebrovascular disease
* Have proliferative retinopathy or maculopathy requiring acute treatment
* Have a serious concomitant systemic disorder including but not limited to HIV or active Hep B or Hep C
* Have been diagnosed and/or treated for malignancy within 3 years
* Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,
Study design
Enrollment target: 40 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2026-09-29
Estimated completion: 2027-06
Last updated: 2026-11-10
Interventions
Drug: Cadisegliatin 800 mg QDDrug: Placebo
Primary outcomes
- • To assess the change in Time in Range (TIR) (last 2 weeks of the two 6-week treatment periods)
Sponsor
vTv Therapeutics · industry
Contacts & investigators
ContactMeaghan Marnell · contact · clinicaltrials@vtvtherapeutics.com · (336) 888-0435
InvestigatorMaria Alba, MD · study_director, vTv Therapeutics LLC
All locations (6)
Paradigm Clinical Research -ModestoRecruiting
Modesto, California, United States
Paradigm Clinical Research Centers, LLCRecruiting
San Diego, California, United States
Barbara Davis Center for DiabetesRecruiting
Aurora, Colorado, United States
Atlanta Diabetes AssociatesRecruiting
Atlanta, Georgia, United States
UNC Eastowne Medical Office BuildingRecruiting
Chapel Hill, North Carolina, United States
Texas Diabetes & Endocrinology, P.A.Recruiting
Austin, Texas, United States